Executive · Scientist · Operator
Sean X. Hu
Sean X. Hu is the President and CEO of Rapafusyn Pharmaceuticals, a Baltimore-based biotech spun out of Johns Hopkins that is building a library of natural-product-like macrocycles it calls RapaGlues. He is a genomics PhD turned Wharton MBA turned management consultant turned operator, with prior stops at Bristol Myers Squibb, CuraGen, Illumina, AT Kearney, IMS, Bionest, BioStrat, GlobalData, and Avotres. In September 2025 he closed an oversubscribed $44M Series A led by BioTrack Capital and Yonjin Capital to push RapaGlues into difficult-to-drug targets.